The Clinical Course of the Late Toxicity of Definitive Radiotherapy in Cervical Cancer

被引:1
作者
Lee, So Jung [1 ]
Kim, Myungsoo [1 ]
Kwak, Yoo-Kang [1 ]
Kang, Hye Jin [1 ]
机构
[1] Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Radiat Oncol, Seoul 06591, South Korea
来源
MEDICINA-LITHUANIA | 2024年 / 60卷 / 08期
关键词
cervix cancer; onset; prevalence; late toxicity; radiotherapy; INDUCED HEMORRHAGIC CYSTITIS; IMAGE-GUIDED BRACHYTHERAPY; HYPERBARIC-OXYGEN; RADIATION; COMPLICATIONS;
D O I
10.3390/medicina60081364
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: This study aimed to investigate the clinical course and characteristics of late toxicity over time following the completion of definitive radiotherapy (RT) in patients with cervical cancer. Materials and Methods: We retrospectively reviewed the medical records of 60 patients with cervical cancer who underwent pelvic external beam radiotherapy followed by intracavitary brachytherapy. Late toxicity was assessed for the lower gastrointestinal (GI) tract and bladder organ at 6, 12, 24, 36, and >36 months post-RT. We examined the onset and prevalence of late toxicity at each time point. Clinical remission and interventions for managing late toxicity were also investigated. Results: The peak onset of lower GI toxicity occurred 12 months after RT completion, with a median symptom duration of 9.9 months (range, 0.1-26.3 months), and exhibited its highest prevalence rate of 15.5% at 24 months post-RT. Most GI toxicities developed and resolved within three years post-RT, with a prevalence rate of 8.1% at three years, followed by a decreasing trend. Bladder toxicity first peaked at 24 months post-RT and continued to occur beyond 36 months, showing the re-increasing pattern in the prevalence rate after 36 months (23.5%). In terms of clinical remission, 66.7% of lower GI toxicities (12 of 18 patients) and 60% of bladder toxicities (9 of 15 patients) achieved complete remission by the last follow-up date. Conclusions: Late toxicities of the GI and bladder following definitive RT in cervical cancer are partially reversible and exhibit distinct patterns of onset and prevalence over time. A systematic follow-up strategy should be established for the early detection and timely intervention of late toxicity by understanding these clinical courses.
引用
收藏
页数:10
相关论文
共 50 条
[21]   Encrusted cystitis after definitive radiotherapy for cervical cancer: a case report [J].
Perrucci, Elisabetta ;
Lancellotta, Valentina ;
di Benedetto, Maika ;
Palumbo, Isabella ;
Matrone, Fabio ;
Chiodi, Marino ;
Lombi, Riccardo ;
Marcantonini, Marta ;
Mariucci, Cristina ;
Aristei, Cynthia .
JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (06) :541-543
[22]   Predictive factors of uterine movement during definitive radiotherapy for cervical cancer [J].
Maemoto, Hitoshi ;
Toita, Takafumi ;
Ariga, Takuro ;
Heianna, Joichi ;
Yamashiro, Tsuneo ;
Murayama, Sadayuki .
JOURNAL OF RADIATION RESEARCH, 2017, 58 (03) :397-404
[23]   Predictive factors of posttreatment fracture by definitive radiotherapy for uterine cervical cancer [J].
Ishikawa, Kazuki ;
Yamashiro, Tsuneo ;
Ariga, Takuro ;
Toita, Takafumi ;
Kudaka, Wataru ;
Heianna, Joichi ;
Maemoto, Hitoshi ;
Kusada, Takeaki ;
Makino, Wataru ;
Aoki, Yoichi ;
Murayama, Sadayuki .
JAPANESE JOURNAL OF RADIOLOGY, 2021, 39 (01) :93-99
[24]   The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy [J].
Mabuchi, Seiji ;
Morishige, Kenichirou ;
Fujita, Masami ;
Tsutsui, Tateki ;
Sakata, Masahiro ;
Enomoto, Takayuki ;
Kimura, Tadashi .
GYNECOLOGIC ONCOLOGY, 2009, 113 (02) :200-204
[25]   Predictive factors of posttreatment fracture by definitive radiotherapy for uterine cervical cancer [J].
Kazuki Ishikawa ;
Tsuneo Yamashiro ;
Takuro Ariga ;
Takafumi Toita ;
Wataru Kudaka ;
Joichi Heianna ;
Hitoshi Maemoto ;
Takeaki Kusada ;
Wataru Makino ;
Yoichi Aoki ;
Sadayuki Murayama .
Japanese Journal of Radiology, 2021, 39 :93-99
[26]   Prospective analysis of patient-reported late toxicity following pelvic radiotherapy for gynaecological cancer [J].
Barraclough, Lisa H. ;
Routledge, Jacqueline A. ;
Farnell, Damian J. J. ;
Burns, Meriel P. ;
Swindell, Ric ;
Livsey, Jacqueline E. ;
Davidson, Susan E. .
RADIOTHERAPY AND ONCOLOGY, 2012, 103 (03) :327-332
[27]   Intensity-modulated Radiotherapy and Anal Cancer: Clinical Outcome and Late Toxicity Assessment [J].
De Francesco, I. ;
Thomas, K. ;
Wedlake, L. ;
Tait, D. .
CLINICAL ONCOLOGY, 2016, 28 (09) :604-610
[28]   A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer [J].
Kirwan, JM ;
Symonds, P ;
Greene, JA ;
Tierney, J ;
Collingwood, M ;
Williams, CJ .
RADIOTHERAPY AND ONCOLOGY, 2003, 68 (03) :217-226
[29]   Clinical outcomes and prognostic factors of definitive radiotherapy for esophageal cancer [J].
Tonoiso, Chisato ;
Ikushima, Hitoshi ;
Kubo, Akiko ;
Kawanaka, Takashi ;
Furutani, Shunsuke ;
Kudo, Takaharu ;
Yoshida, Takahiro ;
Miyamoto, Hiroshi ;
Harada, Masafumi ;
Takayama, Tetsuji ;
Tangoku, Akira .
JOURNAL OF MEDICAL INVESTIGATION, 2019, 66 (1-2) :99-105
[30]   Definitive chemo-radiotherapy in cervical oesophageal cancer: a comprehensive review of literature [J].
Mehta, Ankita ;
Vadgaonkar, Rohit Avinash ;
Lewis, Shirley ;
Mahantshetty, Umesh ;
Agarwal, J. P. .
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2024, 29 (03) :391-408